Compare BW & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BW | NBTX |
|---|---|---|
| Founded | 1867 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 919.9M | 1.0B |
| IPO Year | N/A | 2018 |
| Metric | BW | NBTX |
|---|---|---|
| Price | $15.00 | $28.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $7.00 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 5.0M | 45.0K |
| Earning Date | 03-04-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.57 | N/A |
| Revenue Next Year | $66.70 | $11.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $2.99 |
| 52 Week High | $15.68 | $41.89 |
| Indicator | BW | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.83 | 47.16 |
| Support Level | $8.03 | $20.11 |
| Resistance Level | N/A | $30.23 |
| Average True Range (ATR) | 1.65 | 2.61 |
| MACD | 0.25 | -0.76 |
| Stochastic Oscillator | 82.57 | 1.93 |
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.